Echo(1) | $15,000,000 | (Aug 1, 2025)
KredosAi | Undisclosed Amount | (Aug 1, 2025)
Cline | $32,000,000 | (Aug 1, 2025)
Certified by Founder
Lodge
OrsoBio
start up
United States
- Palo Alto, CA
- 08/11/2023
- Series A
- $60,000,000
OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat severe metabolic disorders, including type 2 diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis. OrsoBio currently has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism.
- Industry Biotechnology Research
- Website https://orsobio.com/
- LinkedIn https://www.linkedin.com/company/orsobio/about/
Moonshine AI | Undisclosed Amount | (Aug 1, 2025)
Noma Security | $100,000,000 | (Aug 1, 2025)
Anaconda, Inc. | $150,000,000 | (Aug 1, 2025)
Nebulock | $8,500,000 | (Aug 1, 2025)
MyPrize | $21,000,000 | (Aug 1, 2025)
Safe Security | $70,000,000 | (Aug 1, 2025)
Merso | $3,000,000 | (Aug 1, 2025)
Metaforms | $9,000,000 | (Aug 1, 2025)
Ultromics | $55,000,000 | (Jul 31, 2025)